StockData
Cytosorbents Corp logo

Cytosorbents Corp (CTSO) stock

CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 19, 2026Score 2/30
$5.57+1.05 (+23.12%)

Close on Nov 18, 2026Market cap $349.72MP/E –Yield –

Cytosorbents gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Cytosorbents's gross profit for the twelve months ending Sep 30, 2026 was $27.31M, up 5.3% year over year. For fiscal 2025 it was $26.49M, up 6.4% from the year before. Over ten years it grew 26.2% a year on average. The highest annual figure on record is $32.12M in fiscal 2021.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$26.49M+6.4%
FY2024Dec 31, 2024$24.89M+13.4%
FY2023Dec 31, 2023$21.95M+5.9%
FY2022Dec 31, 2022$20.73M-35.4%
FY2021Dec 31, 2021$32.12M+7.2%
FY2020Dec 31, 2020$29.95M+70.3%
FY2019Dec 31, 2019$17.59M+17.1%
FY2018Dec 31, 2018$15.01M+55.9%
FY2017Dec 31, 2017$9.63M+72.8%
FY2016Dec 31, 2016$5.57M+116.1%
FY2015Dec 31, 2015$2.58M+29.7%
FY2014Dec 31, 2014$1.99M+289.1%
FY2013Dec 31, 2013$511.10K-50.1%
FY2012Dec 31, 2012$1.02M+4109.4%
FY2011Dec 31, 2011$24.32K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$7.33M+9.9%
Q2 FY2026Jun 30, 2026$7.05M+3.4%
Q1 FY2026Mar 31, 2026$6.13M-1.2%
Q4 FY2025Dec 31, 2025$6.80M+8.8%
Q3 FY2025Sep 30, 2025$6.67M+26.8%
Q2 FY2025Jun 30, 2025$6.81M+4.8%
Q1 FY2025Mar 31, 2025$6.21M-9.7%
Q4 FY2024Dec 31, 2024$6.26M+17.8%
Q3 FY2024Sep 30, 2024$5.26M-6.3%
Q2 FY2024Jun 30, 2024$6.50M+8.0%
Q1 FY2024Mar 31, 2024$6.87M+26.0%
Q4 FY2023Dec 31, 2023$5.31M-7.7%
Q3 FY2023Sep 30, 2023$5.61M+55.0%
Q2 FY2023Jun 30, 2023$6.02M+21.7%
Q1 FY2023Mar 31, 2023$5.46M-14.9%
Q4 FY2022Dec 31, 2022$5.76M-24.8%
Q3 FY2022Sep 30, 2022$3.62M-50.4%
Q2 FY2022Jun 30, 2022$4.94M-46.9%
Q1 FY2022Mar 31, 2022$6.41M-18.3%
Q4 FY2021Dec 31, 2021$7.66M-18.8%
Q3 FY2021Sep 30, 2021$7.30M-4.7%
Q2 FY2021Jun 30, 2021$9.31M+42.3%
Q1 FY2021Mar 31, 2021$7.85M+24.1%
Q4 FY2020Dec 31, 2020$9.43M+76.7%
Q3 FY2020Sep 30, 2020$7.66M+74.1%
Q2 FY2020Jun 30, 2020$6.55M+48.8%
Q1 FY2020Mar 31, 2020$6.32M+83.1%
Q4 FY2019Dec 31, 2019$5.34M+33.5%
Q3 FY2019Sep 30, 2019$4.40M+19.2%
Q2 FY2019Jun 30, 2019$4.40M+10.8%
Q1 FY2019Mar 31, 2019$3.45M+2.9%
Q4 FY2018Dec 31, 2018$4.00M+18.2%
Q3 FY2018Sep 30, 2018$3.69M+59.9%
Q2 FY2018Jun 30, 2018$3.97M+90.5%
Q1 FY2018Mar 31, 2018$3.36M+80.6%
Q4 FY2017Dec 31, 2017$3.38M+89.3%
Q3 FY2017Sep 30, 2017$2.31M–
Q2 FY2017Jun 30, 2017$2.08M–
Q1 FY2017Mar 31, 2017$1.86M–
Q4 FY2016Dec 31, 2016$1.79M–

More Cytosorbents figures

See a number that looks wrong?